Core Viewpoint - Junsheng Tai Pharmaceutical-B (02511) experienced a nearly 8% increase in stock price, reaching HKD 3.4, with a trading volume of HKD 5.8183 million [1] Financial Performance - The company reported a decrease in other income to RMB 10.542 million, a year-on-year decline of 69.96% [1] - Shareholder loss narrowed to RMB 120 million, a year-on-year reduction of 42.96% [1] - Basic loss per share was RMB 0.27 [1] Product Development - The core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system [1] - HTD1801 is under global development for treating CKM-related diseases, including Type 2 Diabetes Mellitus (T2DM), Metabolic Associated Fatty Liver Disease (MASH), Chronic Kidney Disease (CKD), Obesity, Primary Sclerosing Cholangitis (PSC), and Severe Hypertriglyceridemia (SHTG) [1]
港股异动 | 君圣泰医药-B(02511)涨近8% 上半年亏损同比收窄42.96%